TEL AVIV, Israel, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) (the “Company”), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary non-stimulant drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today highly statistically significant positive results from a Phase IIb clinical trial with MG01CI in adults with Predominantly Inattentive Attention Deficit Hyperactivity Disorder (PI-ADHD).
Help employers find you! Check out all the jobs and post your resume.
